Trial Profile
The effects of Suvorexant, a novel orexin receptor antagonist, on physical and cognitive functions after nocturnal forced-awakening
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2020
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary) ; Brotizolam
- Indications Insomnia
- Focus Pharmacodynamics
- 01 Jul 2016 New trial record